摘要
目的运用白血病MIC分型法鉴定SCID-人白血病模型,探求SCID-人白血病模型建立的适宜条件。方法①按接种方式和鼠龄的不同将SCID小鼠平均分为4组。Ⅱ、Ⅰ组鼠龄小于5周,Ⅲ、Ⅳ组鼠龄大于5周。分别以静脉接种、腹腔接种（6-10）×10^6HL-60细胞/鼠建立SCID-人白血病模型。不能发生白血病者用予60Co外照射后再接种。②运用白血病MIC分型法鉴定SCID-人白血病模型：形态学检查包括外周血、腹水涂片的细胞学检查和组织的病理学检查;免疫学检查采用流式细胞分析组织中CD33阳性率;分子遗传学检查骨髓细胞染色体。结果①鼠龄小于5周的Ⅱ、Ⅰ组的SCID小鼠接种HL-60细胞后4周,外周血白细胞上升至（10.±2.2）×10^9/L;2周时小鼠外周血中开始出现HL-60细胞,4周时比例达到（8.7±3.0）%,全部发生白血病。而鼠龄大于5周的Ⅲ、Ⅳ组小鼠小部分发病,未发病者予60Co 200 cGy/鼠,再接种2×10^6HL-60细胞/鼠,也能全部发病。②腹腔接种者实体瘤的发生更为多见,大量腹水,恶病质明显;病理学检查和免疫学检查发现静脉接种者表现为脏器浸润较腹腔接种者广泛、明显,其全身弥漫性扩散的特点与人白血病的临床特点较为一致。③Ⅲ组小鼠经照射后再接种后发生的白血病在全身的广泛浸润程度较同样静脉接种的Ⅰ组更为明显。④鼠龄小于5周的静脉接种组（Ⅰ组）中一发病小鼠给予某不过血脑屏障的药物治疗后,发生了中枢白血病。结论在适当控制SCID小鼠剩余的免疫防御系统后,采用静脉接种,数量为（6-10）×10^6/鼠,能发生全身弥漫性扩散性白血病,且还能模拟出化疗后庇护所白血病的发生。SCID-人白血病模型是一个体内研究人类白血病治疗良好的模型。
Objective To explore the matching requirements of establishing human myeloid leukemia SCID mice model, verified by Morphology Immunology Cytogenetics （MIC）. Methods ①The SCID mice were divided into four groups by different age and inoculating method. Age of five weeks was the divide water shed. Group Ⅰ and Ⅲ, Group Ⅱ and Ⅳ were inoculated via intra perhoneal （i. p. ） and tail vein（i, v. ） with （6-10）× 10^6 HL-60 cell respectively. The SCID mice without leukaemia were inoculated again, after sublethally irradiated with 200 cGy from a ^60Co source. ② The xenograft model of human leukemia was verified by Morphology （peripheral blood, ascites and several organs）, Immunology （Ratio of CD33-positive cells in peripheral blood, liver, lung, kidney, brain, bone marrow analyzed by FCM）, Cytogenetics （chromosome of HL-60 ceils in SCID mice＇s bone marrow）. Results ①Group Ⅰ and Ⅱ,within five weeks old, all develop human leukemia after four weeks. The SCID mice, without leukemia in the other groups, gained their ends, after being irradiated and inoculated again with 2× 10^6 HL-60 cell. ② Ascites and solid tumor grew faster in those groups injected via i.p. Leukemia cell seminated wider in those groups injected via i. v. verified by Morphology Immunology. ③The organs＇ infiltration（liver, spleen and bone marrow） in group Ⅲ（irradiated） was broader and more serious than group Ⅰ （unirradiated）. ④Group Ⅰ develop central nerve system leukemia after chemo-therapy. Conclusion The xenograft model of human leukemia could be well established, by controlling the immunity of SCID mice, inoculated via i.v. with （6-10） × 10^6 HL-60 cell. The character leukemia in SCID mice was wide-infiltrating, consistent with that of human leukemia. Furth more, shelter leukemia could be simulated in SCID mice. This model was a useful tool for stu ying pathogenesis and experimental treatment of human leukemia.
出处
《江西医学院学报》
2007年第3期5-9,12,共6页
Acta Academiae Medicinae Jiangxi
